NBDF is pleased to inform U.S.-based clinicians and other interested individuals of a new series of virtual educational opportunities organized by our friends at the Irish Haemophilia Society (IHS). The IHS is hosting a series of clinical webinars on key topics developed for healthcare providers practicing in the global bleeding disorders community. The six webinars will be held on Zoom during the months of October, November, and December. Please note that these activities are free, but each webinar will require a separate registration.
The program will include the following topics and presenters-
October 28th
“New Therapeutic Possibilities for von Willebrand Disease”
Speaker: Professor David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario
November 11th
“Monitoring Liver Health in Haemophilia”
Speaker: Dr. Vincenzo La Mura, Associate Professor of Internal Medicine, Department of Pathophysiology, Surgery and Transplantation, University of Milan, Milan
November 18th
“Rebalancing Agents in Haemophilia and Other Bleeding Disorders”
Speaker: Dr. Johnny Mahlangu, Head of the Hematology Diagnostic Section in the Department of Molecular Medicine and Haematology at the University of the Witwatersrand, Johannesburg
November 26th
“Update on Gene Therapy and Gene Editing in Haemophilia”
Speaker: Professor David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario
December 2nd
“Update on Mimetics”
Speaker: Dr. Peter Lenting, National Institute for Health and Medical Research, Paris
December 11th
“Access to Treatment – What Has Been Achieved and What is Needed”
Speaker: Dr. Glenn Pierce, Vice President Medical of the World Federation of Hemophilia (WFH), USA
All webinars will be held live at the following time-
7pm-8pm GMT // 8pm-9pm CET // 2pm-3pm EST
Visit the series homepage for more information and to register for these activities.
The IHS Clinical Webinar Series is supported by unrestricted educational grants from Novo Nordisk, Roche, and Takeda.
